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Abstract 
Dysregulated expression of bone morphogenetic protein receptor type II (BMPR2) is a 
pathogenetic hallmark of pulmonary hypertension. Downregulation of BMPR2 protein but not 
mRNA has been observed in multiple animal models mimicking the disease, indicating a 
posttranscriptional mechanism of regulation. Since microRNAs (miRNAs) regulate gene 
expression mainly through inhibition of target gene translation, we hypothesized that miRNAs 
may play a role in the modulation of BMPR2. Performing a computational algorithm on the 
BMPR2 gene, several miRNAs encoded by the microRNA cluster 17/92 (miR-17/92) were 
retrieved as potential regulators. Ectopic overexpression of miR-17/92 resulted in a strong 
reduction of the BMPR2 protein and a reporter gene system showed that BMPR2 is directly 
targeted by miR-17-5p and miR-20a. By stimulation experiments, we found that the miR-
17/92 cluster is modulated by interleukin (IL-)6, a cytokine involved in the pathogenesis of 
pulmonary hypertension. Since IL-6 signaling is mainly mediated by signal transducer and 
activator of transcription (STAT)3, the expression of STAT3 was knocked down by siRNA, 
which abolished the IL-6-mediated expression of miR-17/92. Consistent with these data, we 
found a highly conserved STAT3 binding site in the promoter region of the miR-17/92 gene 
(C13orf25). Promoter studies confirmed that IL-6 enhances transcription of C13orf25 through 
this distinct region. Finally, we showed that persistent activation of STAT3 leads to repressed 
protein expression of BMPR2. Taken together, we describe here a novel STAT3 - miR-17/92 
- BMPR2 pathway thus providing a mechanistic explanation for the loss of BMPR2 in the 
development of pulmonary hypertension.   
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Introduction 
Pulmonary hypertension is a devastating condition defined by the sustained elevation of 
pulmonary vascular resistance that leads rapidly to right heart failure and death when left 
untreated.1 The pathogenesis of pulmonary hypertension is characterized by vascular 
remodelling and vasoconstriction.2 Many chemotactic and inflammatory factors have been 
associated with these vascular changes including interleukin (IL-)-6 and transforming growth 
factor (TGF).3–5 In familial pulmonary arterial hypertension, germline mutations in the gene 
encoding the type II receptor of the bone morphogenetic protein (BMPR2) comprise a genetic 
hallmark of the disease.6 BMPR2 is a surface protein receptor that belongs to the transforming 
growth factor (TGF)  family. Its expression on endothelial and vascular smooth muscle cells 
mediates binding of bone morphogenetic proteins (BMP) that have been identified as 
inhibitors of vascular smooth muscle cell proliferation while inducing cell death.7 It thus was 
suggested that the downregulation of BMPR2 might lead to significant alterations in these 
signaling cascades and, ultimately, to remodelling of the pulmonary vascular bed.8 Of interest, 
alterations in the surface expression of BMPR2 have also been described in non-genetic forms 
of pulmonary hypertension.9 In addition, loss of BMPR2 has been observed in several animal 
models mimicking the disease.8,10 The intracellular mechanisms leading to this 
downregulation however are yet to be elucidated. Studies focussing on the role of BMPR2 in 
the development of pulmonary arterial hypertension have observed reduced protein level of 
this surface receptor. Takahasi et al., for example, described the expression of BMPR2 in 
pulmonary arteries of rats under normal conditions and after exposure to hypoxic conditions. 
Thereby, hypoxia was found to reduce the expression of BMPR2 on the protein levels, 
whereas the levels of the corresponding mRNA were not affected adequately.8 Similarly, in 
the monocrotaline-induced rat model of pulmonary hypertension, the expression of the 
BMPR2 protein was rapidly reduced without initial effects on the mRNA levels.10  
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These findings suggest a post-transcriptional mechanism, such as the involvement of 
microRNAs (miRNAs) that bind to their target mRNAs by Watson-Crick-base pairing at 
distinct seed regions and, thus, alter mRNA stability or affect protein translation. 
An accumulating body of evidence suggests that up to one third of the human genome is 
regulated by miRNAs through post-transcriptional mechanisms.11 Consequently, miRNAs 
have been associated with various cellular processes including cell death, differentiation and 
proliferation.12 Based on computational algorithms (i.e. TargetScan) and the fact that surface 
protein receptors such as the TGF-receptor type II (TGFR have already been shown to be 
regulated by microRNAs,13 we identified the microRNA cluster 17/92 as potential modulator 
of BMPR2 expression. In the present in vitro study, we used human pulmonary arterial 
endothelial cells (HPAEC), hepatocellular carcinoma (HepG2) cells and human embryonic 
kidney (HEK)293 cells to address the following issues: (i) the role of miR-17/92 in the post-
transcriptional regulation of BMPR2 expression; (ii) the effects of inflammatory cytokines 
and growth factors on the expression of miR-17/92; and, (iii) the role of the transcription 
factor signal transducer and activator of transcription (STAT)3 as master link between IL-6 
and the modulation of BMPR2. Our data reveal for the first time a potential molecular 
mechanism explaining the downregulation of BMPR2 in the development of pulmonary 
arterial hypertension. 
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Materials and Methods 
Cell culture. For cell culture, human embryonic kidney (HEK)293 cells and human 
hepatocellular carcinoma (HepG2) cells were used. Human pulmonary artery endothelial cells 
(HPAEC) were purchased from Cascade Biologics. All growth factors and stimulation agents 
(recombinant human IL-6, VEGF, PDGF) were purchased from R&D Systems.  
Plasmid construction. For overexpression of the miR-17/92 cluster, genomic DNA encoding 
miR-17/92 was amplified and cloned into pcDNA3.1 + between the HindIII and EcoRI 
restriction sites as previously described.14 Cells were transfected using Lipofectamine 2000. 
 Real time RT-PCR analysis. Total RNA was extracted using the RNeasy kit and 
quantification of specific RNA transcripts was performed by SYBR Green real-time PCRs, 
using the ABI Prism 7700 Sequence Detection System.  
Quantification of mature microRNA-20a. Total RNA was extracted using the mirVana 
miRNA Isolation Kit. Mature microRNA-20a was detected by stem-loop reverse transcription 
followed by SYBR Green real-time PCR15 and normalized to the expression of 
glyceraldehyde 3-phosphate dehydrogenase.  
Western blot analysis. The following antibodies were used for Western blot: anti - human 
BMPR2, anti - human STAT3, anti - human Phospho-STAT3 and anti - α-Tubulin. Evaluation 
of the expression of specific proteins was performed by the Alpha Imager Software system 
via pixel quantification of the electronic image.  
Reporter gene assay. A 1554 bp fragment of the 3’untranslated region (UTR) of BMPR2 was 
amplified out of genomic DNA. The PCR product was XbaI digested and cloned into the XbaI 
restriction site of the pGL3 control vector. As negative control, the anti-sense construct was 
used according to Kuhn et al.16 HEK293 cells were transfected with the pGL3 control 3‘UTR 
of BMPR2 “sense” or “anti-sense” construct. A vector encoding for the miR-17/92 cluster 
(pcDNA miR-17/92) and a vector for normalisation (pRL-SV40) were added. For inhibition 
of endogenous miRNAs, a similar protocol was applied with the use of anti-miRs. Luciferase 
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activity was measured using the Dual-Luciferase Reporter Assay System and the values 
obtained were normalized to the activity of Renilla luciferase.  
Nuclear transfection. The endogenous expression of the human STAT3 gene was knocked 
down by validated siRNA for STAT3. Nuclear transfection of HPAEC was achieved by using 
the nucleofection kit HMVEC-L from Amaxa.  
Statistics. For statistical analysis, GraphPad Prism Software was used.  
All details are provided within the expanded Materials and Methods section in the online data 
supplement (http://circres.ahajournals.org). 
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Results 
Computational analysis reveals BMPR2 as a target of the miR-17/92 cluster  
Data from previous studies on the protein expression of BMPR2 in animal models of 
pulmonary hypertension suggested a post-transcriptional mechanism of regulation, possibly 
involving miRNAs. We thus performed a screening based on a computational algorithm 
(TargetScan, Whitehead Institute for Biomedical Research, www.targetscan.org) to identify 
distinct seed regions of miRNAs in the 3’untranslated region (UTR) of the BMPR2 gene. To 
improve prediction rates the focus was put only on highly conserved seed regions.17 
TargetScan retrieved several miRNAs for BMPR2, including miR-17-5p, miR-19a, miR-19b, 
miR-20a and miR-92. Of interest, these miRNAs are encoded by one single miRNA cluster, 
miR-17/92 located at the chromosome 13q31 in the 3rd intron of the C13orf25 gene.18  
 
Overexpression of miR-17/92 reduces the expression of BMPR2 
To verify the predicted miRNAs from the computational analysis on a functional basis, the 
entire cluster was cloned into a mammalian expression vector under the control of the SV40 
promoter. Successful overexpression in HEK293 cells was confirmed by quantification of one 
representative mature microRNA derived from miR-17/92 (miR-20a) 72h after transfection. 
As shown in Figure 1a, the expression of miR-20a was significantly increased by 2.71 ± 0.45 
fold (p = 0.005) as compared to the transfection with the empty vector (mock). The 
overexpression of the miR-17/92 cluster resulted in a significant decrease of BMPR2 on the 
protein level as analysed by Western blot (0.66 ± 0.06, p = 0.002, Fig. 1b). The time-
dependent down-regulation is shown as supplementary Figure (Online Fig. I).  The 
corresponding levels of mRNA were also significantly reduced (0.89 ± 0.06, p = 0.03, Fig. 
1c). However, the changes observed on the mRNA level were much less impressive than the 
protein changes, indicating that the miRNA cluster represses the translation process of 
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BMPR2. The modest downregulation of mRNA levels, on the other hand, is a known 
phenomenon reflecting the interactive behaviour of miRNAs and mRNA.19  
 
The reduction of BMPR2 is mediated directly by the action of miR-17-5p and miR-20a 
In a next step, we addressed the question whether the observed reduction of BMPR2 protein is 
directly miRNA-driven. A part of the 3’UTR of BMPR2 (35 – 1589 bp) was cloned into the 
pGL3 control vector creating a luciferase reporter system with respective binding sites for the 
miRNAs 17-5p, 19a, 19b, 20a and 92 (Online Fig. II). The “anti-sense” construct was 
generated and employed as negative control.16 Luciferase activity was assessed, and data were 
normalized to the Renilla luciferase activity. Co-transfection of the pGL3 3’UTR of BMPR2 
“sense” construct and the miR-17/92 overexpressing vector yielded a lower relative luciferase 
activity as compared to mock when transfected into HEK293 cells (0.76 ± 0.12, Fig. 2a). The 
“anti-sense” construct was not affected by overexpression of the miR-17/92 cluster (1.06 ± 
0.07). These findings imply a direct interaction between the 3’UTR of BMPR2 and the 
miRNAs derived from the miR-17/92 cluster. To identify the impact of the distinct miRNAs, 
each endogenous miRNA from the cluster was inhibited by the use of anti-sense RNA 
molecules (anti-miRs). As shown in Figure 2b, these blocking experiments revealed a 
significantly higher relative luciferase activity for anti-miR-17-5p (1.31 ± 0.21, p = 0.03) and 
anti-miR-20a (1.52 ± 0.24, p = 0.008), indicating a pivotal role of these two miRNAs in the 
interaction with the BMPR2. 
 
The expression of miR-17/92 correlates with the activity of STAT3 
A growing body of evidence suggests that the intracellular level of some miRNAs is 
regulated, at least in part, by the action of cytokines20 and growth factors.21 Since these factors 
have also been implicated in the pathogenesis of pulmonary hypertension4 we stimulated 
CIRCRESAHA/2009/197491/R1 9
HPAEC with IL-6, VEGF and PDGF and quantified the expression of the preliminary 
transcript of miR-17/92 (C13orf25).  
Figure 3a illustrates a significant upregulation of C13orf25 mRNA 30min and 1h after the 
stimulation of HPAEC with IL-6 (1.98 ± 0.19, p = 0.0018 and 1.87 ± 0.33, p = 0.045 
respectively) and VEGF (1.96 ± 0.36, p = 0.045 and 1.58 ± 0.03, p = 0.001 respectively) as 
compared to unstimulated control cells. 4h after stimulation, the mRNA levels reached base 
line expression. The stimulation with PDGF did not affect the mRNA levels of C13orf25, 
probably due to the fact that HPAEC lack the receptor for PDGF (data not shown). 
  
It was reported from previous experiments in endothelial cells, that IL-6 and VEGF share 
common signaling mechanisms including the STAT3 pathway.22,23 STAT3 is a major 
transcription factor, which is shuttled from the cytoplasm into the nucleus upon activation by 
tyrosine phosphorylation of residue 705. When HPAEC were stimulated and analysed by 
Western blotting, a strong phosphorylation of STAT3 could be observed for IL-6 after 30 
min, and, to a lesser extent, after 1h. However, no phosphorylation could be detected after the 
addition of VEGF (Fig. 3b). With respect to the data presented in Figure 3a, a correlation 
between activation of STAT3 and induction of the expression of C13orf25 can be postulated. 
According to this hypothesis, we performed siRNA experiments to knockdown the 
endogenous STAT3 expression in HPAEC. Thereby, as shown in Fig 3c, the expression of 
STAT3 could be reduced by 50%. Stimulation experiments after established siRNA-mediated 
reduction of STAT3 are summarized in Figure 3d. Interestingly, the stimulatory effect of IL-6 
on the expression of C13orf25 was almost completely abolished by the functional knockdown 
of STAT3 as compared to stimulated scrambled control cells (p = 0.0027). Consistent with the 
Western blot (Fig. 3b), the difference observed between siRNA and scrambled transfected 
cells when stimulated with VEGF was statistically significant but considerably weaker than 
the difference upon stimulation with IL-6 (p = 0.0428).  To evaluate whether stimulation of 
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HPAEC with IL-6 and VEGF might also affect the expression of mature miRNA derived 
from miR-17/92, expression levels of mature miR-20a were assessed and a significant 
upregulation was detected (1.44  ± 0.31, p = 0.033, Fig. 3e) as compared to control cells 24h 
after stimulation with IL-6. Expression levels of miR-20a measured after stimulation with 
VEGF however did not reach a statistically significant increase (1.44  ± 0.61, p = 0.187). 
These data highlight the role of IL-6 as an inducer of mature microRNAs derived from the 
cluster miR-17/92. 
 
Identification of a highly conserved STAT3 binding site in the promoter of C13orf25 
Since the previous experiments revealed an essential role of STAT3 for the induction of 
C13orf25, as a next step, a screening for STAT3 binding sites in the promoter of C13orf25 
was assessed (TFsearch, Computational Biology Research Center, AIST, Japan, 
www.cbrc.jp/research/db/TFSEARCH.html) and revealed a binding site app. 100 bp upstream 
of the respective start codon. Alignment of this region with several mammalian species is 
shown in Figure 4a and underscores the evolutionary conservation of this binding site. To 
confirm this potential binding site, promoter activity studies were performed. We thus 
inserted the promoter of C13orf25 upstream to a luciferase reporter construct (pGL3 basic 
promoter wildtype, WT). In addition, the sequence of the predicted binding site was altered by 
introduction of three point mutations and used as control (pGL3 basic promoter STAT3). 
Transfection was performed in an IL-6 responsive tumor cell line (HepG2). Stimulation of 
these cells with IL-6 yielded a higher relative luciferase activity of the promoter WT (1.62 ± 
0.41) as compared to the mutated promoter construct (STAT3, 1.04 ± 0.25, p = 0.027, Fig. 
4b) indicating the functional importance of this motif in the IL-6 mediated activation of 
C13orf25 transcription.  
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Transfection of persistent activated STAT3 downregulates the expression levels of BMPR2 in 
an in vitro system 
To investigate the question whether the activation of STAT3 might affect the protein levels of 
BMPR2 through changes in the expression levels of miR-17/92, human STAT3 and a 
constitutively active form of human STAT3, STAT3-C, were cloned.24 To prevent 
experimental cross-reaction by overexpression of STAT3, HEK293 cells were used that 
express endogenous STAT3 in low amounts only. As positive read-out, the mRNA expression 
of suppressor of cytokine signaling (SOCS3), a well-known target gene of STAT3,25 was 
quantified. Overexpression of the wildtype form of STAT3 resulted in increased levels of 
SOCS3 as compared to mock transfected cells (2.16 ± 0.79). This effect was even enhanced 
by the introduction of constitutively active STAT3-C (4.52 ± 2.59, Fig. 5a), thus confirming 
the accurate construction of this molecule. The same samples were further analysed for the 
expression of miR-20a as a representative of mature miRNAs derived from miR-17/92 (Fig. 
5b). Thereby, a similar expression pattern was seen in HEK293 cells for miR-20a as for 
SOCS3, showing significantly increased miR-20a levels in STAT3 WT transfected cells (1.6 
± 0.24, p = 0.016) and STAT3-C transfected cells (2.89 ± 0.63, p = 0.03). These data 
emphasize that the STAT3 pathway modulates the expression of mature miRNAs encoded by 
the miR-17/92 cluster.  
The data presented so far showed that (i) the BMPR2 gene is regulated on a post-
transcriptional level by miR-17-5p and miR-20a; and that (ii) the activation of STAT3 
upregulates the preliminary transcript C13orf25 and the mature miR-20a. To link these 
findings, STAT3-C was overexpressed in HEK293 cells and, subsequently, the BMPR2 
expression was analysed after 96h (Fig 5c). Analysis of the mRNA levels of BMPR2 revealed 
no significant changes (0.94 ± 0.45 fold compared to mock) as shown in panel A. Conversely, 
the protein expression of BMPR2 was found to be reduced by app. 30% after constitutive 
activation of STAT3 (Fig. 5d).  
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Discussion 
 
In the present study, we found that (i) the protein expression of BMPR2 is modulated by the 
miR-17/92 cluster without affecting the BMPR2 mRNA levels; (ii) that this regulatory effect 
is driven by two distinct miRNAs, i.e. miR-17-5 and miR-20a through conserved seed 
matches within the 3’UTR of BMPR2; (iii) that IL-6 regulates the expression of the 
miR-17/92 in human pulmonary arterial endothelial cells by signaling through STAT3. 
Moreover, we could show that (iiii) the promoter region of C13orf25 exhibits an evolutionary 
conserved STAT3 binding site; and, finally, (iiiii) that persistent activation of STAT3 leads to 
a strong upregulation of mature miR-20a, which, in turn, reduces the expression of BMPR2 
protein. Taken together, our findings offer a novel mechanistic explanation for the 
downregulation of BMPR2, which has been repeatedly described as important feature in the 
pathogenesis of pulmonary hypertension.  
 
The cell surface receptor BMPR2 is essential for the modulation of differentiation, 
proliferation and the fibrous matrix production of both endothelial and smooth muscle cells. 
26,7 Changes in the expression of BMPR2 thus might promote vascular remodelling as 
observed in the arterial vessels of patients with pulmonary hypertension. This hypothesis is 
supported by the fact that the loss of BMPR2 due to germline mutations is a hallmark of 
genetic forms of pulmonary hypertension and, moreover, that reduced BMPR2 levels in the 
pulmonary arteries have been described in several animal models of pulmonary 
hypertension.8,10 The regulation of BMPR2 however is poorly understood so far, but results 
from previous studies suggest a post-transcriptional mechanism of regulation.8,10 In this field, 
miRNAs have emerged as novel molecular players. The data presented here comprise to our 
knowledge the first report on the modulation of BMPR2 by microRNAs.  
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We approached the experiments by performing a computational screening that revealed 
multiple miRNAs as potential regulators of BMPR2. The highest prediction rates however 
were yielded for the miRNAs derived from the miRNA-17/92 cluster located in the 3rd intron 
of the C13orf25 gene. It was previously shown that this polycistronic region encodes for six 
mature microRNAs (i.e. the miR-17/92 cluster: miR-17-5p, miR-18a, miR-19a, miR-19b, 
miR-20a, and miR-92).18 To investigate the role of these miRNAs in the regulation of 
BMPR2, we employed a mammalian pcDNA expression vector encoding for miR-17/92. 
Transient overexpression of this cluster led to a reduction of BMPR2 protein levels, whereas 
the mRNA levels remained unchanged. These results confirmed the hypothesis of a post-
transcriptional role of miR-17/92 in the regulation of BMPR2. To proof whether these 
miRNAs directly interact with the 3’UTR of BMPR2, we further constructed a reporter gene 
system containing a luciferase gene and the predicted seed matches for miR-17/92. This assay 
showed repressed luciferase activity following overexpression of miR-17/92 thus verifying a 
direct binding of these miRNAs. Conversely, elevated levels of luciferase activity were found 
after blocking the endogenous miRNAs by using individually designed anti-miRs. In 
particular, we could show that the 3’UTR of BMPR2 is a direct target of two distinct 
microRNAs, i.e. miR-17-5p and miR-20a, derived from the miR-17/92 cluster. Consistent 
with these data, TGFR2, another receptor from the identical protein family, is also targeted 
by the miR-17/92 cluster.13 TGFR2 is a major mediator of tissue fibrosis and has been 
associated with the pathogenesis of pulmonary hypertension.27 Moreover, it has been found 
that the TGFR2 protein is almost absent in plexiform lesions that characterize the aberrant 
endothelial proliferation in idiopathic pulmonary arterial hypertension.28 Whether the 
miRNAs derived from the cluster 17/92 regulate TGFR2 and BMPR2 alike and, thus, might 
provide a final common pathway in the remodelling of pulmonary arterial vessels has to be 
addressed by further studies. 
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The gene C13orf25 was first described as target for chromosomal amplification in malignant 
lymphoma.29 This gene attracted primary attention after several studies suggested oncogenic 
activities probably due to targeting tumor suppressor genes, such as Bim and PTEN.30 
Moreover, Suarez and co-workers showed that the miR-17/92 cluster is pivotally involved in 
the angiogenic sprouting of human endothelial cells.31 Recent observations demonstrated that 
the expression pattern of miRNAs derived from miR-17/92 is regulated by a number of 
known transcription factors. O’Donnell and co-workers, for example, described the 
modulation of miR-17/92 by c-Myc14 and the data on this regulatory network have recently 
been extended by Woods et al. showing a direct interaction of E2F3 with the promoter region 
of C13orf25.32   
In our experiments, we provide evidence that the promoter of C13orf25 also bears a 
functional binding site for STAT3, which controls the transcription of several genes involved 
in the inflammatory response.33 By applying promoter studies we confirmed a STAT3-
responsive region located about 100 bp upstream of the start codon of C13orf25. The 
functional importance of these findings is highlighted by the fact that this region was found to 
be phylogenetically conserved among mammalian species. In all species investigated, the 
distance of the STAT3-binding site to the respective sequence encoding for miR-17/92 
revealed to span between 3200 and 4500 bp. Interestingly, a similar distance was described 
recently for the other known STAT3-regulated miRNA (i.e. miR-21),20 indicating a common 
evolutionary assembly of miRNA genes regulated by this transcription factor.  
In normal cells, the expression and phosphorylation of STAT3 is finely balanced by negative 
feedback loops including the activation of SOCS proteins.25 These feedback mechanisms 
might however be bypassed through persistent upstream signaling or through knock-down of 
inhibitory proteins leading to constitutively activated STAT3. Such phenomena have been 
found in several human tumors.34 Of interest, a constitutive activation of STAT3 has also 
been described in human arterial endothelial cells derived from patients with pulmonary 
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hypertension.35 In general, the imitation of aberrant signaling by overexpression of 
persistently activated STAT3 displays an interesting experimental approach to identify novel 
miRNAs regulated directly or indirectly through inflammatory responses. The results obtained 
by such strategies might help to understand the reasons for altered miRNA expression profiles 
in these conditions. Along this line, we constructed such an expression vector for STAT3,24 
and subsequent transfection of this vector promptly resulted in increased levels of mature 
miR-20a as compared to mock or STAT3 wildtype transfected cells. Since this experimental 
setup reduced the expression of BMPR2 protein but not the respective mRNA, we suggest 
that this effect is driven, at least in part, by the upregulation of miRNAs derived from the 
cluster miR-17/92.  
 
STAT3 was first described in the downstream signaling of IL-6 modulating acute phase gene 
expression.36 Intriguingly, patients with pulmonary hypertension were found to have higher 
serum levels of IL-6 as compared to healthy controls3 and the ectopic administration of IL-6 
has been observed to induce a mild elevation of the pulmonary arterial pressure in mice.37,38 
Moreover, the important role of IL-6 in the pathogenesis of pulmonary hypertension has been 
underpinned by a recent study in transgenic mice overexpressing IL-6. When compared to 
their wildtype counterparts, these animals developed increased ventricular systolic pressures, 
right ventricular hypertrophy and pulmonary vasculopathic changes indicative for pulmonary 
hypertension.5 In the present study, we thus investigated the influence of IL-6 on the 
expression of C13orf25 in HPAEC, and found that IL-6 induced the gene expression of miR-
17/92 in a STAT3-dependent manner.  
 
Our data offer a direct link between the action of IL-6 and the expression of the miR-17/92 
cluster. Since STAT3 has been shown to activate also the transcription of the c-myc gene,39 
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our findings highlight the role of IL-6 in the regulatory pathway that controls the expression 
of miR-17/92 and thus complements this network by a novel piece (Figure 6).  
 
Finally, our data allow us to conclude that increased IL-6 signaling leads to the 
downregulation of BMPR2, based on a phylogenetically conserved STAT3 - miR-17/92 
pathway. It could be speculated that STAT3 plays an important role in the development of 
pulmonary hypertension, in particular since it has been shown that a persistently activated 
STAT3 promotes cell survival of HPAEC derived from patients with pulmonary arterial 
hypertension. As we could further show that STAT3 regulates the BMPR2 expression through 
transcriptional activation of miR-17/92, one might postulate this cluster as a highly specific 
target for the causative treatment of pulmonary hypertension. Since inhibitors of miRNAs are 
not available in a clinical setting at this moment, the inhibition of STAT3 activation by anti-
cytokine therapies directed against IL-6 might provide a feasible alternative to restore 
functional levels of BMPR2. 
Taken together, we provide here for the first time a mechanistic explanation for the loss of 
BMPR2 in pulmonary hypertension shedding novel light on the pathogenesis of this disease 
and related conditions.  
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Figure legends 
 
Figure 1: 
Overexpression of miR-17/92 in HEK293 cells.  
HEK293 cells were transfected with the pcDNA miR-17/92 vector, and mRNA and protein 
were collected 72h later. A) Quantification of miR-20a showed a significant upregulation by 
2.71 ± 0.45 fold as compared to mock transfection. B) Transient overexpression of the 
miR-17/92 cluster led to a 40% decrease of BMRP2 protein as analysed by Western blot. C) 
Levels of BMPR2 mRNA were slightly reduced (0.89 ± 0.06). Data are shown as mean ± SD 
derived from 4 independent experiments. 
 
Figure 2: 
Reporter gene studies on the interaction between 3’UTR of BMPR2 and the miR-17/92 
cluster in HEK293 cells. 
A) Co-transfection of the pGL3 3’UTR of BMPR2 “sense” construct and the miR-17/92 
overexpressing vector resulted in a significantly lower relative luciferase activity as compared 
to the “anti-sense” construct (p = 0.0047). B) Blocking experiments with the use of anti-sense 
RNA molecules (anti-miRs) directed against each miRNA revealed a significantly higher 
relative luciferase activity for anti-miR-17-5p and anti-miR-20a. Data are shown as mean ± 
SD derived from 4 independent experiments. 
 
Figure 3: 
Correlation between the expression of miR-17/92 and the activity of STAT3 in HPAEC. 
A) Quantification of the preliminary transcript of miR-17/92 (C13orf25). Stimulation of 
HPAEC with IL-6 and VEGF but not PDGF significantly increased the expression of 
C13orf25 mRNA. B) Phosphorylation of STAT3 at tyrosine residue 705 could be observed 
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for IL-6 in a time dependent manner, whereas no effect was seen for the stimulation with 
VEGF. C) siRNA-mediated knockdown reduced the expression of STAT3 by 50% on the 
protein level. D) The induction of C13orf25 mRNA by IL-6 was almost completely abolished 
by the functional knockdown of STAT3 as compared to stimulated scrambled control cells (p 
= 0.0027). The effect observed by stimulation with VEGF was less strong but still reached 
statistical significance (p = 0.0428). E) Stimulation of HPAECs for 24h revealed significant 
upregulation of miR-20a after stimulation with IL-6 (p = 0.033). Data are shown as mean ± 
SD derived from 4 independent experiments. 
 
Figure 4: 
Identification of a highly conserved STAT3 binding site in the promoter of C13orf25. 
A) A 33 bp region in the promoter of C13orf25 contains a predicted STAT3 binding site. 
Alignment of this region with several mammalian species highlights the evolutionary 
conservation of this binding site (adapted from 20). B) Reporter gene assay studies. 
Stimulation of HepG2 cells with IL-6 resulted in a higher relative luciferase activity of the 
promoter WT as compared to the mutated promoter construct (STAT3). Data are blotted as 
median including lower and upper whisker. 5 independent experiments performed. 
 
Figure 5: 
Transient transfection of constitutively active STAT3 downregulates BMPR2 in vitro. 
A) Quantification of SOCS3 mRNA in transfected HEK293 cells after 48h. Overexpression of 
both STAT3-WT and STAT3-C resulted in increased levels of SOCS3 as compared to mock 
transfected cells. B) Analysis of miR-20a expression performed in identical RNA extracts as 
in panel A. Levels of miR-20a were found upregulated in STAT3-WT and STAT3-C 
transfected cells when compared to mock transfected cells. C) Quantification of BMPR2 
mRNA in STAT3-C transfected HEK293 cells after 96h. The mRNA levels of BMPR2 was 
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found unchanged as compared to mock. D) Western blot for BMPR2 in STAT3-C transfected 
HEK293 cells after 96h showed a reduction of protein expression. Data are shown as mean ± 
SD derived from 4 independent experiments. 
 
Figure 6: 
Mechanism of regulation of BMPR2. 
The transcription of miR-17/92 is regulated by c-Myc and E2F3.14,32 In the present study, we 
demonstrate that the promoter region of miR-17/92 also bears a functional binding site for 
STAT3. The latent transcription factor STAT3 is the major mediator of IL-6 signaling. With 
respect to the fact that STAT3 induces the expression of c-Myc,39 IL-6 emerges as a new 
modulator of miR-17/92. It is known that microRNAs derived from this cluster target the 
surface receptor TGFβR2.13 Here we provide evidence that the related BMPR2 is modulated 
by miR-17/92 alike. 
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